Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Dec 5;18(12):2627.
doi: 10.3390/ijms18122627.

Immunotherapy for Prostate Cancer: Where We Are Headed

Giuseppe Schepisi  1 , Alberto Farolfi  2 , Vincenza Conteduca  3 , Filippo Martignano  4 , Delia De Lisi  5 , Giorgia Ravaglia  6 , Lorena Rossi  7 , Cecilia Menna  8 , Salvatore Roberto Bellia  9 , Domenico Barone  10 , Roberta Gunelli  11 , Ugo De Giorgi  12
Affiliations
Review

Immunotherapy for Prostate Cancer: Where We Are Headed

Giuseppe Schepisi et al. Int J Mol Sci. .

Abstract

Prostate cancer is one of the most common malignant neoplasms in men worldwide, and is the fifth cause of cancer-related death. In recent years, a new generation of therapies have been approved for the management of metastatic disease. Moreover, the development of new immunotherapeutic drugs has become a novel frontier for the treatment of several tumor types; to date, numerous studies have investigated their potential activity, including in prostate cancer. In this article, we discuss the role of emerging immunotherapeutic drugs in prostate cancer patients.

Keywords: CTLA4; PD-L1; PD1; antibodies; immunotherapy; prostate cancer; vaccines.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Immune Checkpoint Inhibitors based on CTLA-4 and PD-1/PD-L1 blockade in prostate cancer. Abbreviations. MHC, major histocompatibility complex; TCR, T-cell receptor. Black continuous line: indicates an enlargement of the figure to which it refers; Black arrow line indicates an activation of the previous cell(s).
See this image and copyright information in PMC

References

    1. Flammiger A., Bayer F., Cirugeda-Kuhnert A., Huland H., Tennstedt P., Simon R., Minner S., Bokemeyer C., Sauter G., Schlomm T., et al. Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancer. APMIS. 2012;120:901–908. doi: 10.1111/j.1600-0463.2012.02924.x. - DOI - PubMed
    1. Ebelt K., Babaryka G., Frankenberger B., Stief C.G., Eisenmenger W., Kirchner T., Schendel D.J., Noessner E. Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters. Eur. J. Cancer. 2009;45:1664–1672. doi: 10.1016/j.ejca.2009.02.015. - DOI - PubMed
    1. Sfanos K.S., Bruno T.C., Meeker A.K., De Marzo A.M., Isaacs W.B., Drake C.G. Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+ Prostate. 2009;69:1694–1703. doi: 10.1002/pros.21020. - DOI - PMC - PubMed
    1. Ammirante M., Luo J.L., Grivennikov S., Nedospasov S., Karin M. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature. 2010;464:302–305. doi: 10.1038/nature08782. - DOI - PMC - PubMed
    1. Ammirante M., Kuraishy A.I., Shalapour S., Strasner A., Ramirez-Sanchez C., Zhang W., Shabaik A., Karin M. An IKKalpha-E2F1-BMI1 cascade activated by infiltrating B cells controls prostate regeneration and tumor recurrence. Genes Dev. 2013;27:1435–1440. doi: 10.1101/gad.220202.113. - DOI - PMC - PubMed

Substances